NCT02135445View on ClinicalTrials.gov

Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Prostate Cancer
Interventions
DRUG

TAK-385

TAK-385 tablet

DRUG

Degarelix

Degarelix injection

Trial Locations (25)

Unknown

Birmingham

San Diego

Denver

Bradenton

Daytona Beach

Fort Lauderdale

Fort Myers

Plantation

Jeffersonville

Wichita

Shreveport

Omaha

Syracuse

Columbus

Eugene

Myrtle Beach

Dallas

San Antonio

Virginia Beach

Brighton

Manchester

Metropolitan Borough of Wirral

Taunton

Sutton

Birmingham

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY